First 10-year follow-up shows that treatment with AVONEX leads to long-term benefits in early multiple sclerosis patients

SEATTLE, WA April 30, 2009 Biogen Idec (NASDAQ: BIIB) today announced data results from the CHAMPIONS (Controlled High-Risk AVONEX (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subj...

First ten-year follow-up shows that treatment with AVONEX leads to long-term benefits in early multiple sclerosis patients

SEATTLE, WA April 30, 2009 Biogen Idec (NASDAQ: BIIB) today announced data results from the CHAMPIONS (Controlled High-Risk AVONEX (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subj...

New data show patients using avonex reported less sick leave and short-term disability costs

Denver, CO June 2, 2008 Results from an analysis assessing the differences in health benefits costs (HBCs) and lost time among employees suffering from multiple sclerosis (MS) being treated with injectable disease modifying therapies (DMTs) were presented and announced by Biogen Idec as poster p...

MS Patients More Compliant with Medications When Managed by Specialty Pharmacy, According to HealthCore Study Presented at ISPOR

... with 79 percent managed and 21 percent non-managed. The median age was 46 years and the majority was female. More than one-third of the patients used avonex as index medication, while others used Copaxone (31 percent), Rebif (17 percent), Betaseron (14 percent) and Tysabri (less than 1 percent). Abou...

Study shows that high-dose, high-frequency interferon produces no additional benefit

...V, open label, head-to-head study of intramuscular avonex and high-dose, high-frequency subcutaneous Rebif (...and Retrospective Long-Term Observational Study of avonex and Rebif (PROOF), involved 217 patients with 136 completing a median of 25.9 months of avonex 30 mcg once weekly (n=69) and a median of 22.2 mon...

New Data Suggests Progression of Disability at Two Years Predicts Multiple Sclerosis (MS) Disability Progression at Eight Years

...(RRMS). The analysis suggests that patients taking avonex for two years were less likely to experience disab...atment (81 placebo, 79 interferon beta-1a), in the avonex Phase III trial and who were re-examined eight yea...ysis revealed: -- Patients initially treated with avonex were less likely than patients initially recei...

Multiple Sclerosis Patients to Benefit With AVONEX(R) Nurse Services Program

...," said Marie Stallbaum, RN, BSN, a nurse with the avonex Nurse Services Program. "Nurses in this program wi...fullest and most active lives possible." The avonex Nurse Services program will have registered nurses...side effects ?Valuable phone counseling "The avonex Nurse Services program is the latest example of ou...

AVONEX in Medical Technology

New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 13, 2007 - Biogen Idec Inc. (NASDAQ: BIIB) announced today that one-year data presented at the Academy of Managed Care Pharmacy's (AMCP) 2007 Annual Meeting show that AVONEX(R) (Interferon beta-1a) is a cost-effective therapy in multiple sclerosis (MS) when co...

Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line

...patients. "Surveyed neurologists' responses suggest that Biogen Idec's avonex is more at-risk than Teva's Copaxone of losing share upon the launch of either oral cladribine or fingolimod, as more physicians cite avonex as having potential for being replaced by either emerging oral agent," stat...

AVONEX in Biological Technology

Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning

...e Officer of Tengion. "Mark brings extensive experience and a proven track record in both large pharma and biotech, including the successful launch of avonex for multiple sclerosis. His broad expertise in managing commercial activities across all stages of product development, and in specialty markets, will...

Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis

...est in first-line therapy. "The low volume of patient share attributed to avonex or Rebif compared with Copaxone in first- and second-line treatment illustr...h-dose, high-frequency agent reaches patient shares close to and surpassing avonex in first- and second-line treatment, respectively." According to the new ...

Olympics of biotechnology has international flavor

...cer. 1991 : Genzyme's Ceredase is approved by the FDA to treat Gaucher's disease and had 2006 sales of over $1 billion. 1996 : Biogen's drug avonex for multiple schlerosis is approved by the FDA, also with sales of over $1 billion annually. 2003 : The Broad Institute founded in Cambridge to g...